Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Ubiquitinated deiodinase: not dead yet
Ronald J. Koenig
Ronald J. Koenig
Published July 15, 2003
Citation Information: J Clin Invest. 2003;112(2):145-147. https://doi.org/10.1172/JCI19157.
View: Text | PDF
Commentary

Ubiquitinated deiodinase: not dead yet

  • Text
  • PDF
Abstract

Originating in the thyroid, the prohormone thyroxine is converted to triiodothyronine, which is essential in brain development, growth, and metabolism. A study in this issue reveals a novel mechanism for controlling triiodothyronine production that provides the first example of enzyme activity being restored by deubiquitination.

Authors

Ronald J. Koenig

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Thyroid hormone metabolism and action in different cell types. (a) Hepat...
Thyroid hormone metabolism and action in different cell types. (a) Hepatocytes (which express D1), as a model for cells that do not express D2. D1 converts plasma T4 to T3, but this T3 does not have direct access to the cell nucleus. Plasma T3 enters the nucleus. In the euthyroid state, TRs are about 50% T3-occupied and target genes are induced proportionately. (b) BAT, as a model for tissues that express D2. Plasma T3 enters the nucleus. In addition, the ER enzyme D2 converts T4 to T3, which has direct access to the nucleus, resulting in a high level of TR occupancy by T3. Target genes are induced proportionately. D2 is regulated by metabolic perturbations, e.g., cold exposure (via norepinephrine) in BAT. The catalytic activity of D2 stimulates its ubiquitination and potential degradation in proteasomes. However, the VDUs can prevent degradation and recover enzyme activity by deubiquitinating Ub-D2. In BAT, VDU1 itself is induced by cold exposure, via norepinephrine. In some tissues, VDUs are ubiquitinated by pVHL and degraded, but this has not been studied in BAT. The retinoid X receptor (RXR) is the dimerization partner for TR.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts